June 2024 in “Poster presentations” Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.
December 2025 in “npj Breast Cancer” Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.
October 2025 in “Frontiers in Medicine” Ixekizumab has known and some unexpected side effects.
45 citations
,
July 2025 in “Journal of Medicinal Chemistry” The document discusses the submission of a New Drug Application (NDA) to the U.S. FDA for vepdegestrant (ARV-471), a PROTAC protein degrader targeting the estrogen receptor, by Arvinas and Pfizer. This submission is based on positive results from the Phase 3 VERITAC-2 trial and marks a significant milestone as vepdegestrant is anticipated to be the first FDA-approved PROTAC degrader. PROTACs, a novel class of molecules, selectively degrade disease-causing proteins and offer advantages over traditional small molecule inhibitors, such as mitigating off-target effects and overcoming drug resistance. Despite concerns about their large molecular weight and drug-like properties, recent clinical results have been promising. The success of PROTACs has inspired the development of other chimeric molecules for therapeutic applications.
25 citations
,
March 2017 in “International Journal of Dermatology” Ruxolitinib effectively and safely regrows hair in alopecia patients.
32 citations
,
October 2004 in “Pharmacotherapy” Peginterferon alfa-2b and ribavirin therapy for hepatitis C can cause serious side effects, some different from those reported in clinical trials.
130 citations
,
October 2006 in “Allergy” Allergic reactions to blood thinners are rare but can be serious, requiring careful testing and alternative treatments.
September 2025 in “Value in Health” 
February 2026 in “Indian Journal of Skin Allergy” Ruxolitinib cream effectively treats skin conditions like atopic dermatitis and vitiligo with minimal side effects.
2 citations
,
May 2020 in “JAAD case reports” Ruxolitinib can cause a delayed skin reaction on the nose.
December 2025 in “Dermatology Reports” Topical ruxolitinib quickly improves non-segmental vitiligo.
January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
January 2024 in “Journal of Crohn's and colitis” Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
September 2023 in “Journal of the American Academy of Dermatology” Ixekizumab is safe for long-term use with low rates of major heart-related events.
May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly” 
November 2009 in “Hair transplant forum international” Doctors should collaborate with the patient's primary care physician to decide if it's safe to stop taking Plavix before hair restoration surgery, considering the risk and benefit.
322 citations
,
October 2006 in “British Journal of Clinical Pharmacology” Warfarin is effective but risky, requiring careful monitoring to prevent bleeding.
January 2025 in “The Journal of Dermatology” Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.
July 2024 in “Reactions Weekly” 
March 2020 in “Section 5: Patient safety and quality assurance” Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.
January 2026 in “Nutrición Hospitalaria” Many drugs can cause lipid metabolism issues, and labels need better warnings.
6 citations
,
November 2023 in “Clinical Pharmacokinetics” Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
1 citations
,
April 2016 in “Journal of The American Academy of Dermatology” A woman had a delayed allergic reaction to the blood thinner enoxaparin, treated with a steroid cream.
16 citations
,
February 2009 in “Clinical neurology and neurosurgery” Switching to extended-release divalproex sodium improved patient-reported tremor but did not change seizure frequency or most side effects.
2 citations
,
December 2023 in “Journal of clinical immunology” Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.
3 citations
,
January 2016 in “Case reports in dermatological medicine” An 80-year-old man grew extra hair on his forearms after starting Alzheimer's medication rivastigmine.
June 2020 in “Zenodo (CERN European Organization for Nuclear Research)” 
October 2025 in “Actualización en Medicina de Familia” New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.
5 citations
,
May 2022 in “Clinical & Experimental Metastasis” Minoxidil and ranolazine together can reduce the spread of certain breast cancer cells.